What can you do to prevent drug-induced hearing loss ?
Learn how to insulate your development program from ototoxicity
Watch the full video
Fighting against Covid-19 and ototoxicity
Learn how to fight
MAKING HEARING A PRIORITY
CILcare is the world’s leading R&D services company committed to making hearing a priority. Take an in-depth look at how we can support your R&D program to prevent and treat ear disorders.
Discover our services
BIO Korea 2021 Replay : Noise-induced hearing loss and ageing : physiopathology & strategies for preclinical development
Do you want to learn more on noise-induced hearing loss and ageing? Which strategies can you choose for a successful preclinical development? Find out by watching this presentation given by Dr Wahid Awad, CILcare's Chief Business Officer, at BIO Korea 2021 during a...
CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market
Montpellier & Seoul, June 8th, 2021: CILcare, the world’s leading CRO dedicated to ear disorders, and Knotus, a leading Korean non-clinical CRO, announced today that they have entered into a strategic partnership that aims at accelerating the development of...
BIO Korea is an elite Korean event that gathers experts and academics from the bio industry, not only to present technological information, but mostly to connect innovative actors from the industry to create and discuss opportunities. Taking place on June 9-11 2021,...
Pharma / Biotech
CILcare, the world leading CRO dedicating to ear disorders
Because research & development in hearing is as fascinating as it is complex, preclinical studies require perfectly accurate and reproducible measures using state-of-the-art technology in acoustics and electrophysiology. CILcare’s core values lie in our validated and highly robust animal models, enabling us to deliver consistent and valid results.
Drawing from an extensive industrial background, we guide our partners from target identification to IND, and work closely together to advance auditory research and reach a common goal: serve patient population who need our help the most.
CILcare proposes services to develop innovative solutions for hearing loss, tinnitus, otitis, and ototoxicity
Drugs to treat Hearing Loss and Tinnitus
Drugs and Medical Devices to treat Otitis
Medications safe for the ear (absence of ototoxicity)
Regenerative Therapies: Gene and Cell Therapies
Implantable Drug Delivery Devices and Imaging
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Disabling hearing loss could affect 2.5 billion people globally by 2050 according to the WHO. In 2019, 1.6 billion people were affected. This alarming and rapidly growing prevalence mainly results from population growth and aging, modern lifestyles with excessive noise exposure, the intake of ototoxic drugs, and chronic ear infections.
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 1 trillion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.
“CILcare is definitely more than a simple CRO! Following our work experience in PK/PD studies, CILcare now resonates as a trusted partner, fully committed to the success of their Sponsor’s assets. CILcare’s scientific expertise in the auditory system and neurosciences is no longer in doubt. The robustness of CILcare’s animal models, which highly mimic human ear disorders, gives us the confidence for translational success in clinical phases. It is always a pleasure to work with all the team members, they are very proactive, responsive, and dedicated to their customers.” Carmen Herrero, CSO, Spiral Therapeutics